Chemical Genetics of Transcriptional Regulation by CDKs in Human Cells

人类细胞中 CDK 转录调控的化学遗传学

基本信息

批准号：
8630081
负责人：
ROBERT P FISHER
金额：
$ 32.21万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-02-15 至 2017-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8630081
关键词：
Antineoplastic Agents Antiviral Agents Archaeal RNA Binding Catalytic Domain Cell Cycle Progression Cell Proliferation Cell division Cells Chemicals Chromatin Colon Carcinoma Cyclin-Dependent Kinases DNA Polymerase II DNA-Directed RNA Polymerase Defect Development Drug Targeting Elongation Factor Ensure Enzymes Eukaryota Evaluation Fission Yeast Gene Expression Gene Expression Regulation Genes Genetic Screening Genetic Transcription Genome Human Human Development Human Engineering Human Identifications In Vitro Individual Kinetics Label Malignant Neoplasms Messenger RNA Modeling Normal tissue morphology Organism Orthologous Gene Pathway interactions Pattern Peptide Initiation Factors Pharmaceutical Preparations Phase Phosphorylation Phosphotransferases Play Polymerase Positive Transcriptional Elongation Factor B Process Property Proteins RNA RNA Polymerase II RNA Processing RNA chemical synthesis Reading Recruitment Activity Regulation Role Signal Transduction Staging Testing Time Torpedo Transcript Transcription Elongation Transcription Initiation Transcriptional Regulation Variant Viral Yeasts adenine analog analog base cancer cell chemical genetics chemotherapy chromatin modification chromatin protein crosslink cyclin T1 cyclin-dependent kinase-activating kinase feeding genome-wide human disease in vivo mutant novel novel strategies prevent promoter public health relevance reconstitution research study small molecule transcription factor TFIIE transcription factor TFIIH transcription termination

项目摘要

Project Summary The transcription cycle of RNA polymerase II (Pol II) depends on sequential functions of distinct cyclin-dependent kinases (CDKs), but the mechanisms that order those functions are still emerging. We have taken a chemical-genetic approach-replacement of wild- type with analog-sensitive (AS) mutant CDKs-to reveal both "early" and "late" functions of the CDK network in transcription. First, by selective inhibition of Cdk7-a component of transcription initiation factor TFIIH-in human cells, we uncovered two unexpected, and seemingly antagonistic functions. Cdk7 activity is required to recruit factors that establish a promoter-proximal pause by Pol II, and to activate Cdk9, catalytic subunit of positive transcription elongation factor b (P-TEFb), which releases the pause. Therefore the CDK network appears to depend on incoherent feedforward to raise a transient kinetic barrier to Pol II elongation, and thus create a temporal window to recruit mRNA- processing and chromatin-modifying machinery. Consistent with a requirement for CDK- directed pausing to ensure faithful RNA processing, inhibition of Cdk7 or Cdk9 leads to defects in termination and 3'-end maturation of Pol II transcripts. Second, in a chemical- genetic screen for Cdk9 substrates, we identified multiple proteins involved in RNA 5'- end decapping and the "torpedo" pathway of transcription termination, which has recently been suggested to influence pausing and divergent antisense transcription. We will dissect the initiation-elongation transition of Pol II, and elucidate regulation of transcription termination and polarity, to uncover novel modes of gene regulation by CDKs. The specific aims are: 1. To identify functions and targets of CDKs at the initiation-elongation transition 2. To investigate possible regulation of the transcription termination pathway by P- TEFb, uncovered in a chemical genetic screen for Cdk9 targets 3. To dissect functions of Cdk7 and Cdk9 by chemical genetics in human cells Our studies reveal a CDK cascade at the core of the Pol II transcription cycle; completion of our aims will illuminate how Cdk7 and Cdk9 collaborate to ensure unidirectional transitions between phases of that cycle. By turning CDKs into chemical switches that can be manipulated with customized small molecules, we will distinguish their specific roles and substrates, and reveal new anti-cancer or anti-viral drug targets.

项目摘要 RNA聚合酶II（POL II）的转录周期取决于独特的细胞周期蛋白依赖性激酶（CDKS），但是订购这些功能的机制仍在出现。我们采取了野生的化学遗传学方法的替代键入模拟敏感（AS）突变cdks to可以揭示“早期”和“晚”功能转录中的CDK网络。首先，通过选择性抑制CDK7-A组分在人类细胞中的转录起始因子Tfiih-I-I-IN细胞中，我们发现了两个意外的，和看似对立的功能。 CDK7活动需要招募因素通过POL II建立启动子 - 蛋白暂停，并激活CDK9，催化亚基阳性转录伸长因子B（P-TEFB），该因子释放了停顿。所以 CDK网络似乎取决于不连贯的前馈以提高瞬态动力学延伸的动力障碍，从而创建一个时间窗口来募集mRNA- 加工和染色质修饰机械。与CDK-的要求一致定向暂停以确保忠实的RNA处理，抑制CDK7或CDK9导致 POL II转录本的终止和3端成熟缺陷。第二，在化学中 CDK9底物的遗传筛选，我们确定了与RNA 5'-的多种蛋白质结束decapping和“鱼雷”的转录终止途径，其中最近有人建议影响暂停和不同的反义转录。我们将剖析Pol II的启动 - 延长过渡，并阐明调节转录终止和极性，以发现基因调节的新型模式 CDK。具体目的是： 1。确定在启动 - 延长过渡时CDK的功能和目标 2。研究可能调节p-对转录终止途径的调节 TEFB，在化学遗传筛选中的CDK9目标中发现 3。通过化学遗传学在人类细胞中解剖CDK7和CDK9的功能我们的研究揭示了Pol II转录周期核心的CDK级联反应。我们目标的完成将阐明CDK7和CDK9如何合作以确保该循环阶段之间的单向转变。通过将CDK变成化学可以通过定制的小分子来操纵的开关，我们将区分它们的特定作用和底物，并揭示了新的抗癌或抗病毒药物靶标。